Fasting Study of Controlled-Release Oxycodone Hydrochloride 40 mg Tablets and OxyContin® 40 mg Tablets
Status:
Completed
Trial end date:
2005-04-01
Target enrollment:
Participant gender:
Summary
The objective of this open-label, randomized, two-period, crossover study was to evaluate the
oral bioavailability of the Mallinckrodt controlled-release test tablet formulation of
oxycodone 40 mg compared to an equivalent oral dose of a commercially available
controlled-release tablet of oxycodone (OxyContin® 40 mg, Purdue Pharma L.P.) in a test group
of healthy subjects under fasting conditions.